The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
Improvements were also seen in complete response rates, duration of response, and time to next treatment
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Over 8.8?million Indians aged 60 and above currently live with dementia,
The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society
The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk
GCCL aims to leverage the partnership to expand strategic relationships with global CROs
Subscribe To Our Newsletter & Stay Updated
